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Background: The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We 21 
evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals.  22 
Methods: We performed a survey addressed to patients regularly taking chloroquine and its 23 
derivatives for the control of their autoimmune diseases. The survey was distributed with special 24 
attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to 25 
the general population. A sample of untreated subjects was matched to the treated group according to 26 
sex, age range and incidence region. COVID-19 disease prevalence was compared between treated 27 
and untreated-matched control sample. 28 
Results: A total of 319 surveys of patients regularly taking chloroquine and its derivatives were 29 
recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 30 
5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community 31 
exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated 32 
(17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value=0.027). 33 
Conclusion: We did not find differences of reported COVID-19 cases between treated and untreated 34 
groups, indicating a lack of protection by regular administration of chloroquine and its derivative 35 
drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take 36 
chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection 37 
measures as the general population. 38 
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The search for an effective treatment against SARS-CoV-2 infection has emerged as a worldwide 42 
priority. A promising strategy to fight the virus causing the newest pandemic is the identification of 43 
already available drugs active against other diseases that can be effective also against this new 44 
SARS-CoV-2 infection [1].  45 
We present here an evaluation of the potential protective effect of chloroquine and its derived drugs 46 
on the prevalence of COVID-19 in patients undergoing an active treatment with these drugs. 47 
Chloroquine and its derived drugs such as hydroxychloroquine have shown in vitro and in vivo 48 
effectiveness against viral infections such as SARS [2],
 
influenza A H5N1, and Zika. Chloroquine is 49 
believed to interfere with both the entry and exit of viruses from cells hosts, as well as in the 50 
manifestation of acute respiratory syndrome. The virus enters the cells through binding to the 51 
angiotensin-converting enzyme 2 (ACE2). Chloroquine can reduce ACE2 glycosylation, thereby 52 
preventing viruses from effectively binding to cells [3]. On the other hand, chloroquine accumulates 53 
in lysosomes, increasing the endosome pH levels which interferes with the viral particle release 54 
process [4]. In addition, chloroquine could block the production of proinflammatory cytokines, thus 55 
preventing the pathway that subsequently leads to acute respiratory syndrome [5]. Two recent clinical 56 
trials have presented inconclusive evidence on the effectiveness of chloroquine treatment in COVID-57 
19 disease in Chinese [6] and French [7] populations. Both studies have supported the use of 58 
chloroquine or chloroquine derivatives against COVID-19, however, the design and conclusions of 59 
both studies have been questioned [8]. 60 
Chloroquine and its derivatives such as chloroquine phosphate or hydroxychloroquine are commonly 61 
used in the treatment of autoimmune diseases. Not without serious side effects, the use of these drugs 62 
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under medical prescription is widely spread. It has been proposed hydroxychloroquine as a 63 
prophylaxis treatment against SARS-CoV-2 infection for exposed caregivers [9]. Our hypothesis is 64 
that if chloroquine treatment is effective against SARS-CoV-2 infection, those patients following an 65 
active chloroquine or derivative drug treatment would be protected against the infection or against 66 
COVID-19 adverse effects. Thus, our study aims to test this hypothesis by evaluating the incidence 67 
of COVID-19 disease in the population according to chloroquine treatment subgroups through a 68 
survey.  69 
Material and methods 70 
Survey design and data collection  71 
A survey was designed to be conducted electronically via smartphone or personal computer, and 72 
therefore it was also designed to ensure accessibility and simplicity to facilitate its completion. 73 
Information about the project and a link to the URL of the survey were disseminated in the press and 74 
via social media and email, with special attention to Spanish patient associations centered on 75 
autoimmune diseases and rheumatology. The survey included demographic questions about gender, 76 
age range, and province of residence, as well as questions pertaining to health-status outcomes such 77 
as treatment, COVID-19 diagnosis and symptoms due to COVID-19 infection. In addition, questions 78 
about infection diagnosis and symptoms in close relatives and friends were also included. Because 79 
the first cases of COVID-19 were reported in Spain in March 2020, our survey collects cases that 80 
occurred between March and May 2020. 81 
Individuals of any age above legal age (18 years old) with residence in Spain were eligible for 82 
inclusion in the study. Individuals undergoing a stable chloroquine or derived drug treatment before 83 
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the COVID-19 pandemic were classified as treated (treated group) while individuals without 84 
treatment were classified as untreated (untreated group). 85 
The Clinical Research Ethics Committee of the Hospital Universitari Arnau de Vilanova in Lleida 86 
approved the study (Ref: CEIC-2257).  87 
Statistical analysis 88 
Statistical analyses were performed with R software (v3.6.0) and IBM SPSS v21 (IBM corporation, 89 
NY, USA). Prior to the analysis, reported provinces of residence in Spain were grouped according to 90 
COVID-19 incidence as stated in June 1 by the Spanish Ministry of Health [10] as follows: Incidence 91 
region 1 (incidence<200/100,000 inhabitants) that includes Andalucía, Canarias, Ceuta, Illes Balears, 92 
Melilla and Región de Murcia; Incidence region 2 (incidence 200-500/100,000 inhabitants) that 93 
includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de 94 
Asturias; Incidence region 3 (incidence 500-1,000/100,000 inhabitants) that includes Castilla y León, 95 
Castilla-La Mancha, Catalunya, Euskadi and Navarra; and Incidence region 4 96 
(incidence>1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja. Age 97 
categories were assigned according to the following age ranges: 18-50, 51-65 and >65 years old. 98 
Data on symptoms related to COVID-19 infection were collected and used to assign individuals as 99 
suspected COVID-19 cases when reporting loss of taste or smell and/or three or more COVID-19 100 
associated symptoms [11]. 101 
A sample of untreated subjects was matched to the treated group according to sex, age range and 102 
incidence region with e1071 R package. The matching process was repeated using a bootstrap 103 
strategy and re-sampling of the untreated-matched dataset was repeated 1,000 times to obtain the 104 
distribution and mean values of the descriptive statistics such as age range, gender, incidence region 105 
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and declared COVID-19 prevalence. Comparisons between groups were performed by Fisher exact 106 
test. P-value<0.05 was considered statistically significant. 107 
Results 108 
Overall, 2295 individuals completed the surveys between May and June 2020. From these, data 109 
collection was complete, with all key data for the study, for 2161 individuals (94.2%). Of these 110 
completed surveys, 11 entries did not meet eligibility criteria and were excluded from the analysis. 111 
The final number of completed surveys used for the study was 2150. Among them, 319 (14.8%) were 112 
from patients following an active chloroquine or derived drug treatment and have been included in 113 
the treatment group, and 1831 (85.2%) have been included in the untreated group and serves as the 114 
source to obtain the untreated-matched subgroups. We note that 94% of the treatment group 115 
individuals were following a hydroxychloroquine treatment.  116 
The main descriptive characteristics of both treated (n=319) and untreated-matched (n=319) 117 
subgroups, arranged according to their declared COVID-19 status, are reported in Table 1. 118 
Distribution of declared COVID-19 status did not differ significantly within age group, gender and 119 
incidence region (Table 1). In contrast, having a community exposition (defined as those individuals 120 
declaring a COVID-19 positive case in a close family member or flatmate) was associated with a 121 
greater prevalence of COVID-19 disease when compared with non-exposed individuals in both 122 
treated (17.0%, 95%CI 12.9%-21.1% vs. 3.2%, 95%CI 1.3%-5.2%; p-value<0.001) and untreated 123 
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The prevalence of declared COVID-19 status in the treated group was 5.3% (95%CI 2.9-7.8) and the 129 
mean prevalence among the untreated-matched groups was 3.4% (95%CI 1.4-5.4). Furthermore, the 130 
prevalence of suspected COVID-19 patients in treated subjects was of 18.8% (95%CI 14.5-23.1) and 131 
the mean prevalence among the untreated-matched groups was 15.7% (95%CI 11.7-19.7). These 132 
figures are nearly similar to those recently found in the study of the seroprevalence of IgG antibodies 133 
Table 1 - Demographic characteristics of persons taking chloroquine or derivatives (treated) and matched control sample 
(untreated) according to their declared COVID-19 status 
  
Treated (n=319)  
 











(-) Totals P-value 
Age range, n (%) 
18-50 
 
9 (4.7) 182 (95.3) 191 0.433 
 
6.7 (3.5) 185.4 (96.5) 192.2 0.999 
51-65 
 
8 (7.1) 105 (92.9) 113 
  
3.9 (3.5) 107.5 (96.5) 111.3 
 > 65 
 
0 (0.0) 15 (100.0) 15 
  
0.3 (2.1) 15.2 (97.9) 15.5 
 Total 
 
17 (5.3) 302 (94.7) 319 
  
10.9 (3.4) 308.1 (96.6) 319 
 Sex, n (%) 
Male 
 
1 (4.8) 20 (95.2) 21 0.905 
 
1.1 (5.0) 20.2 (95.0) 21.2 0.973 
Female 
 
16 (5.4) 282 (94.6) 298 
  
9.8 (3.3) 287.9 (96.7) 297.8 
 Total 
 
17 (5.3) 302 (94.7) 319 
  
10.9 (3.4) 308.1 (96.6) 319 
 Incidence regionb, n (%) 
R1 
 
1 (2.4) 40 (97.6) 41 0.420 
 
0.0 (0.0) 41.1 (100.0) 41.1 0.275 
R2 
 
1 (2.8) 35 (97.2) 36 
  
1.0 (3.4) 28.7 (96.6) 29.7 
 R3 
 
11 (5.4) 193 (94.6) 204 
  
6.1 (2.7) 218.8 (97.3) 225.0 
 R4 
 
4 (11.4) 31 (88.6) 35 
  
3.2 (15.9) 17.0 (84.1) 20.2 
 Unknown 
 
0 (0.0) 3 (100.0) 3 
  
0.5 (17.3) 2.5 (82.7) 3.0 
 Total 
 
17 (5.3) 302 (94.7) 319 
  
10.9 (3.4) 308.1 (96.6) 319 
 Community exposition, n (%) 
Exposedc 
 
8 (17.0) 39 (83.0) 47 <0.001 
 
8.2 (13.3) 53.3 (86.7) 61.5 0.027 
Unexposed 
 
7 (3.2) 210 (96.8) 217 
  
2.2 (1.1) 204.4 (98.9) 206.6 
 Unknown 
 
2 (3.6) 53 (96.4) 55 
  
0.5 (1.0) 50.4 (99.0) 50.9 
 Total   17 (5.3) 302 (94.7) 319     10.9 (3.4) 308.1 (96.6) 319   
COVID-19: disease caused by SARS-CoV-2 infection. 
a Mean after 1000 replicates of matched untreated control samples. 
b Regions grouped by incidence of COVID-19. IR1 (incidence <200/100,000 inhabitants) that includes Andalucía, 
Canarias, Ceuta, Illes Balears, Melilla and Región de Murcia; IR2  (incidence 200-500/100,000 inhabitants) that includes 
Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de Asturias; IR3 (incidence 500-
1,000/100,000 inhabitants) that includes Castilla y León, Castilla-La Mancha, Catalunya, Euskadi and Navarra; and IR4 
(incidence >1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja. 
c Exposed were those individuals declaring a COVID-19 positive case in a close family member or flatmate. 
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against SARS-CoV-2 in the Spanish population showing an estimated prevalence of 5% (95%CI 134 
4.7%-5.4%), and a prevalence of suspected COVID-19 cases of nearly 20%.[11] 135 
Discussion 136 
Our results show no differences in COVID-19 prevalence among untreated and chronically treated 137 
individuals with chloroquine or derivative drugs. Independently of the exposure, both groups showed 138 
the same prevalence of COVID-19 disease or suspected COVID-19 disease according to symptoms. 139 
We must note that we found a clear association between the COVID-19 disease prevalence and 140 
exposure to a close family member or flatmate positive for COVID-19 in both, treated and untreated 141 
subjects, that points to a lack of any protective effect on SARS-CoV-2 infection attributable to 142 
chronic treatment with chloroquine or derivative drugs.  143 
We should mention some limitations of our study such as a limited power to detect small changes in 144 
prevalence between treatment groups. However, the design of this study addressed the need to collect 145 
and analyse data within a particularly short period of time due to the rapid onset and progression of 146 
the pandemic, as well as the urgency of identifying and evaluating rapidly possible therapies, thus 147 
partially compensating the reduced sample size. The prevalence of COVID-19 found in our study is 148 
similar to the seroprevalence of IgG antibodies against SARS-CoV-2 in the Spanish population [11], 149 
which is higher than the reported COVID-19 prevalence in the general population based on RNA’s 150 
virus detection [10]. This difference could be attributed to self-reported disease and the diagnosis of 151 
COVID-19 by medical practitioners, which in many cases does not involve results of diagnostic tests 152 
due to the lack of such tests. Finally, we could not eliminate completely the possibility of some bias 153 
due to the intrinsic condition of the individuals within the treatment group that are undergoing 154 
chloroquine or derivative drug treatment due to other diseases that alter their health status and may 155 
have different comorbidities. However, our results are in line with a recent study conducting a 156 
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randomized trial that reported no effect of hydroxychloroquine when used as a post exposure 157 
prophylaxis for COVID-19 [12]. 158 
All these data together point towards a lack of a protective effect of chloroquine or derivative drugs 159 
as a prophylaxis for COVID-19, including prophylactic treatment before and after exposure. Of 160 
relevance, data indicates that people that regularly take chloroquine derivatives are exposed to 161 
SARS-CoV-2 infection and must take the same protection measures as the general population. These 162 
data should be considered in the prevention and treatment protocols made by health policymakers for 163 
the management of the disease in new outbreaks. 164 
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